| Literature DB >> 35062712 |
Svetlana V Dentovskaya1, Anastasia S Vagaiskaya1, Mikhail E Platonov1, Alexandra S Trunyakova1, Sergei A Kotov2, Ekaterina A Krasil'nikova1, Galina M Titareva1, Elizaveta M Mazurina1, Tat'yana V Gapel'chenkova1, Rima Z Shaikhutdinova1, Sergei A Ivanov1, Tat'yana I Kombarova3, Vladimir N Gerasimov2, Vladimir N Uversky4, Andrey P Anisimov1.
Abstract
To develop a modern plague vaccine, we used hypo-endotoxic Yersinia pestis bacterial ghosts (BGs) with combinations of genes encoding the bacteriophage ɸX174 lysis-mediating protein E and/or holin-endolysin systems from λ or L-413C phages. Expression of the protein E gene resulted in the BGs that retained the shape of the original bacterium. Co-expression of this gene with genes coding for holin-endolysin system of the phage L-413C caused formation of structures resembling collapsed sacs. Such structures, which have lost their rigidity, were also formed as a result of the expression of only the L-413C holin-endolysin genes. A similar holin-endolysin system from phage λ containing mutated holin gene S and intact genes R-Rz coding for the endolysins caused generation of mixtures of BGs that had (i) practically preserved and (ii) completely lost their original rigidity. The addition of protein E to the work of this system shifted the equilibrium in the mixture towards the collapsed sacs. The collapse of the structure of BGs can be explained by endolysis of peptidoglycan sacculi. Immunizations of laboratory animals with the variants of BGs followed by infection with a wild-type Y. pestis strain showed that bacterial envelopes protected only cavies. BGs with maximally hydrolyzed peptidoglycan had a greater protectivity compared to BGs with a preserved peptidoglycan skeleton.Entities:
Keywords: Yersinia pestis; bacterial ghost; bubonic plague; guinea pigs; holin-endolysin system; inactivated vaccine; phage; protection; protein-E-mediated lysis; vaccine
Year: 2021 PMID: 35062712 PMCID: PMC8777944 DOI: 10.3390/vaccines10010051
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Bacterial strains, plasmids, and bacteriophages used in this study.
| Strains/Plasmid/Bacteriophage | Relevant Genotype or Annotation | Source |
|---|---|---|
|
| ||
| DH5α | F−, | SCPM-O * |
|
| ||
| 231 | wild type strain; universally virulent (LD50 for mice ≤ 10 CFU, for guinea pigs ≤ 10 CFU); Pgm+, pMT1, pPCP1, pCD− | SCPM-O [ |
| KM260(12) | avirulent derivative of 231; Pgm+, pMT1−, pPCP1−, pCD− | SCPM-O |
| KM260(12)Δ | Δ | SCPM-O |
| KM260(12)Δ | KM260(12)Δ | This study |
| KM260(12)Δ | KM260(12)Δ | This study |
| KM260(12)Δ | KM260(12)Δ | This study |
| KM260(12)Δ | KM260(12)Δ | This study |
| KM260(12)Δ | KM260(12)Δ | This study |
| KM260(12)Δ | KM260(12)Δ | This study |
| Plasmid | ||
| pACYC184 | Source of p15A | [ |
| pBAD/myc-HisA | Source of | Invitrogen |
| pET32b (+) | Source of multiple cloning site | Novagene |
| pEYR’ | Expression vector, phage Lambda modified right promoter (pR’) (Cmr) | SCPM-O |
| pEYR’-E | Lysis plasmid, pEYR’-lysis E (Cmr) | SCPM-O |
| pEYR’-E-Y-K | Lysis plasmid, pEYR’-lysis E, Y, K (Cmr) | SCPM-O |
| pEYR’-Y-K | Lysis plasmid, pEYR’-lysis Y, K (Cmr) | SCPM-O |
| pEYR’-E-S-R-Rz | Lysis plasmid, pEYR’-lysis E, S, R, Rz (Cmr) | SCPM-O |
| pEYR’-S-R-Rz | Lysis plasmid, pEYR’-lysis S, R, Rz (Cmr) | SCPM-O |
| Bacteriophage | ||
| λCE6 | Source of pR promoter, holin ( | Thermo Scientific |
| φX174 | Source of E protein gene | Thermo Scientific |
| L-413C | Source of holin ( | Russian Research Anti-Plague Institute Microbe |
* The State Collection of Pathogenic Microbes and Cell Cultures on the base of the State Research Center for Applied Microbiology and Biotechnology (“SCPM-Obolensk”).
Primers used in this study.
| Name | Sequence |
|---|---|
| pEY-1 (ClaI) | 5′CCC |
| pEY-2 (SphI) | 5′ATATT |
| pEY-5 (NdeI) | 5′GGC |
| pEY-6б | 5′ |
| pEY-7б | 5′ |
| pEY-8 (ClaI) | 5′CCC |
| pR-For (SphI) | 5′CACAAA |
| pR-Rev (NdeI) | 5′GATAC |
| pR (T > C) (NdeI) | 5′GTG |
| E1 (NdeI) | 5′AGG |
| E2 (XhoI) | 5′AAT |
| Y-NdeI (XhoI) | 5′GGTGG |
| Y-SalI (SalI) | 5′GCC |
| K-XhoI (XhoI) | 5′ATT |
| S-R-Rz-For (SalI) | 5′AAA |
| S-R-Rz-Rev (XhoI) | 5′ATT |
* Restriction sites are underlined, ** Complementary sequences are highlighted in italics.
Figure 1Schematic representation of vector and lysis cassettes used in this study.
Figure 2The lysis kinetics of Y. pestis KM260(12)ΔlpxM harboring different lysis plasmids. Lysis was monitored by the measurement of the OD600 (A) and the determination of the number of CFU (B). Y. pestis BGs grown to exponential phase were inactivated by induction of the lysis genes. The CFU counts were transformed to log base 10 values. The data are presented as the mean ± s.d. of three samples.
Figure 3Transmission electron micrographs of Y. pestis strains (A) KM260(12)∆lpxM, (B) KM260(12)∆lpxM) pEYR’-E, (C) KM260(12)∆lpxM/pEYR’-Y-K, (D) KM260(12)∆lpxM/pEYR’-S-R-Rz KM260(12)∆lpxM/pEYR’-S-R-Rz, (E) KM260(12)∆lpxM/pEYR’E-Y-K, (F) KM260(12)∆lpxM pEYR’-E-S-R-Rz. (24 h after the induction).The bar represents 0.1 μm (B–D,F) or 500 nm (A,E).
Figure 4Antibody response in sera of guinea pigs (A) and mice (B) immunized s.c. with E-BG, EYK-BG, YK-BG, SRRz-BG, ESRRz-BG, and PBS, respectively at week 4 post administration. 100 μL of Y. pestis BGs were coated as antigen, the goat anti-mouse IgG-HRP or goat anti-guinea pig IgG-HRP was used as detection antibody. #—p > 0.05; *—p < 0.05; ***—p < 0.001; ****—p < 0.0001.
Figure 5Cytokines levels of splenic lymphocytes from immunized guinea pigs (A) and mice (B). The splenic lymphocytes were isolated on day 14 after the last immunization, and corresponding BGs were used as immunogens. The culture supernatants were harvested after 48 h and the cytokine concentration was measured by ELISA. #—p > 0.05; *—p < 0.05; **—p < 0.005; ***—p < 0.001. ****—p < 0.0001.
Indices of immunity (II) induced by BGs variants.
| Animals Immunized with BGs/Antigen | Guinea Pigs | Mice | ||
|---|---|---|---|---|
| LD50, CFU * | II ** | LD50, CFU | II | |
| …. | 147 | 4.9 × 101 | 32 | 4.6 × 100 |
| Y-K | 6813 | 2.3 × 103 | 22 | 3 × 100 |
| E-Y-K | 146,780 | 4.9 × 104 | 22 | 3 × 100 |
| S-R-Rz | 68 | 2.3 × 101 | 15 | 2 × 100 |
| E-S-R-Rz | 147 | 4.9 × 101 | 46 | 6.6 × 100 |
| F1 ** | 316 | 1.0 × 102 | 100,000 | 1.4 × 104 |
| PBS | 3 | 1 × 100 | 7 | 1 × 100 |
* Values are given as means ±95% confidence intervals. ** The ability of BGs to protect an animal from death after administration of a high dose of a virulent wild type strain, designated Immunity Index (II) was calculated as the ratio: II = LD50/LD50.
Figure 6Protection of YP BGs against a lethal challenge with the wild-type Y. pestis 231 strain. Guinea pigs (A) and mice (B) were subjected to s.c. infection with different BGs strains or F1 at day 0 and boosted at day 14. 14 days after the last immunization, six mice and six guinea pigs from each group were challenged s.c. with 102 CFUs of wild-type Y. pestis 231 (33.3 LD50 for mice and 14.3 LD50 for cavies).